The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 03, 2021

Filed:

Sep. 06, 2018
Applicant:

Shanghai Changzheng Hospital, Shanghai, CN;

Inventors:

Jianru Xiao, Shanghai, CN;

Wanwan Shen, Shanghai, CN;

Xiaopan Cai, Shanghai, CN;

Yiyun Cheng, Shanghai, CN;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); A61K 47/34 (2017.01); C12N 15/113 (2010.01); C12N 15/87 (2006.01); A61K 47/22 (2006.01); A61P 25/18 (2006.01); A61K 47/30 (2006.01); A61P 37/02 (2006.01); A61K 31/353 (2006.01); A61P 17/00 (2006.01); A61P 29/00 (2006.01); A61P 35/00 (2006.01); A61P 5/00 (2006.01); A61P 9/00 (2006.01);
U.S. Cl.
CPC ...
A61K 48/0041 (2013.01); A61K 31/353 (2013.01); A61K 47/22 (2013.01); A61K 47/30 (2013.01); A61K 47/34 (2013.01); A61K 48/00 (2013.01); A61P 5/00 (2018.01); A61P 9/00 (2018.01); A61P 17/00 (2018.01); A61P 25/18 (2018.01); A61P 29/00 (2018.01); A61P 35/00 (2018.01); A61P 37/02 (2018.01); C12N 15/1137 (2013.01); C12N 15/87 (2013.01);
Abstract

A composition for gene therapy or transfection includes nucleic acid, natural polyphenol, and cationic molecules. There are several phenolic hydroxyl groups in the natural polyphenol, so as to eliminate free radicals, prevent cancer, fight inflammation, and provide antioxidants feature. Compared with the delivery of cationic molecules alone, the composition can significantly improve the transfection efficiency by about 60-70%, reduce the dose of effective transfection of cationic molecules by about 20 times, thereby reducing the toxicity of transfection and showing better organism compatibility. The composition of the present invention does not introduce other chemical reagents, does not require synthesis, has high biosafety, and can efficiently and safely deliver a plurality of nucleic acid molecules into cells. The composition can be used as a highly effective and low-toxicity nucleic acid drug in the treatment of gene-related diseases, and has good medicinal value.


Find Patent Forward Citations

Loading…